CardioComm Solutions Completes Meeting With Visiting Japanese Medical Technology Delegates in Toronto

CardioComm Solutions, Inc. (CardioComm Solutions) (TSX VENTURE:EKG) was
identified as a company of interest to participate in a one day exchange (March
7, 2012) of information and ideas with a visiting Japanese medical technology
delegation sponsored by the Ontario's Ministry of Economic Development and
Innovation, in partnership with the Canadian Trade Commissioner Service. The
objectives of the mission were to promote partnership in innovation, R&D, trade
and investment in the area of medical imaging between Canada and Japan.


The one-on-one meetings between CardioComm Solutions and the visiting Japanese
companies explored areas of collaboration which could lead to new
commercialization opportunities for CardioComm Solutions' bio-monitoring
technologies. Given the confidential nature of the meetings and to respect the
wishes of the delegation and the Canadian Trade Commissioner Service, the
participating organizations from the Japanese delegation will not be disclosed
at this date.


CardioComm Solutions is a medical software engineering company specializing in
the management of electrocardiograms ("EKGs"), one of the most common diagnostic
tests performed. Over the past three years the company has successfully launched
solutions that enable the receipt, review and interpretation of EKGs through the
use of newer medical devices and communication portals over internet and
cellular based technologies. Their EKG management solutions can now service both
medical and consumer markets internationally. "Our Global EKG Management System
(GEMS) is comprised of two technologies. The first enables the capture and
importation of EKG recordings from FDA cleared devices such as the
HeartCheck(TM) PEN, Mobile Cardiac Telemetry Devices ("MCT"), 12 lead EKG
machines and cardiac event loop recorders ("ELRS"). Our second proprietary
technology is an EKG "viewer" that forms the core of our family of products
allowing the EKG wave form to be acquired, reviewed, interpreted and saved,
thereby enabling medical professionals to make diagnoses for cardiac
arrhythmias. Our EKG SDK viewer is a technology of specific interest to our
larger clients as it can be integrated to their own proprietary workflow systems
without GEMS(TM)," said Etienne Grima, CEO of CardioComm Solutions.


"Discussions with the visiting delegates highlighted the importance of having
access to ready-to-market and proven medical solutions. The Japanese market is
active in searching out technologies such as ours to service their growing
In-Hospital, Point of Care and Home Monitoring needs. With over 200 million
citizens, the consumer market importance also cannot be understated. Follow up
discussions are planned as well as the potential for a CardioComm Solutions
visit to Japan in 2012," added Grima.


"We were very pleased to have been asked to attend the closed door meetings and
to learn more about Japanese advanced technologies. The meetings also allowed us
to share our plans for leveraging our history of performance in the health care
market as we take first steps towards integrating with new consumer EKG and
other bio-sign monitoring devices under the GEMSTM 4.0 software platform. This
event presented an excellent opportunity for access into the Japanese market, a
medical device market worth approximately $32 billion," said Simi Grosman,
member of the board of directors for CardioComm Solutions.


About CardioComm Solutions

CardioComm Solution's patented and proprietary technology is used in products
for recording, viewing, analyzing and storing electrocardiograms for diagnosis
and management of cardiac patients. CardioComm Solutions also is cleared by the
FDA for the sales of a consumer based HeartCheck(TM) PEN handheld EKG device and
home version of its proprietary GEMS(TM) Home software. Products are sold
worldwide through a combination of an external distribution network and a North
American-based sales team. The company has earned the ISO 13485 certification,
is HPB approved, HIPAA compliant, and has received FDA market clearance for its
software devices. CardioComm Solutions, Inc. is headquartered in Toronto,
Canada, with offices in Victoria, B.C.


Forward-looking statements

This release may contain certain forward-looking statements with respect to the
financial condition, results of operations and business of CardioComm Solutions
and certain of the plans and objectives of CardioComm Solutions with respect to
these items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will
occur in the future and there are many factors that could cause actual results
and developments to differ materially from those expressed or implied by these
forward-looking statements.
Musicrypt Inc. (Tier1) (TSXV:MCT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024